Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
378 GBX | +1.61% | +30.34% | +7.23% |
May. 08 | MaxCyte Shares Rise Sharply After Q1 Results Beat | MT |
May. 08 | MaxCyte shares rise amid double-digit revenue increase | AN |
Business Summary
Number of employees: 143
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Therapy
55.3
%
| 31 | 69.0 % | 23 | 55.3 % | -25.26% |
Program-related
27.8
%
| 5 | 10.4 % | 11 | 27.8 % | +148.38% |
Drug Discovery
16.9
%
| 9 | 20.6 % | 7 | 16.9 % | -23.14% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 44 | 100.0 % | 41 | 100.0 % | -6.72% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 23-03-26 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 04-12-31 |
Corporate Officer/Principal | - | 23-08-20 | |
Gene Zhu
LAW | General Counsel | - | - |
Jill Mayer
HRO | Human Resources Officer | - | 17-12-31 |
Thomas Ross
SAM | Sales & Marketing | 63 | 14-10-14 |
Steven Nardi
PRN | Corporate Officer/Principal | - | 20-10-12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 22-11-30 |
Art Mandell
BRD | Director/Board Member | 71 | 06-04-30 |
Will Brooke
BRD | Director/Board Member | 68 | 04-02-29 |
Stanley Erck
BRD | Director/Board Member | 76 | 04-12-31 |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 04-12-31 |
John Johnston
BRD | Director/Board Member | 65 | 15-12-31 |
Richard Douglas
CHM | Chairman | 71 | 18-02-11 |
Yasir Al-Wakeel
BRD | Director/Board Member | 42 | 21-06-14 |
Rekha Hemrajani
BRD | Director/Board Member | 54 | 21-06-14 |
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 104,544,289 | 98,128,703 ( 93.86 %) | 0 | 93.86 % |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.23% | 488M | |
+11.07% | 225B | |
+11.03% | 186B | |
+13.16% | 135B | |
+26.14% | 107B | |
+0.91% | 63.56B | |
+6.74% | 51.32B | |
+12.35% | 51.04B | |
+8.06% | 43.3B | |
+4.68% | 36.99B |
- Stock Market
- Equities
- MXCT Stock
- Company MaxCyte, Inc.